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We have read the article recently published by Home et al. (1) . This report conveys an important perspective on insulin therapy in patients with type 2 diabetes by a working party of diabetes specialists and comments on optimal insulin management of individuals with this condition. The purpose of this group was to summarize the current published data and review the "evidence and circumstances in which insulin can be used" and "consider individualized choices of alternatives and combination regimens" (1) . However, as the emergence of clinical evidence can be fluid and dynamic, the omission of significant new findings from very recent studies might occur. This occurred with the present article as concurrent with its publication a late-breaking study on the use of continuous subcutaneous insulin infusion (CSII) in people with type 2 diabetes was presented at the American Diabetes Association 2014 Scientific Sessions in San Francisco and recently published online in The Lancet (2) . This OpT2mise study reports the results of a large randomized controlled study comparing patients on multiple daily insulin injections (MDI) using insulin analogs to patients on CSII therapy who were previously unable to reach glycated hemoglobin (HbA 1c ) targets using intensified therapy with MDI regimen. After a 2-month dose-optimization run-in period, patients with HbA 1c $8.0% and #12% were randomized to pump therapy or to continue with MDI for 6 months. The study group consisted of 331 patients (average HbA 1c at randomization 9.0%) with at least 0.7 units/kg of total daily insulin dose (average 112 units per day). This group of patients failing MDI often have limited medical options. In addition, patients with elevated levels of HbA 1c .8.5% (69 mmol/mol), with little or no decrease in HbA 1c with intensive treatment regimen, with obesity and severe insulin resistance are at risk for excess mortality (3, 4) . After 6 months, the study demonstrated that HbA 1c had decreased by 1.1% in the CSII group and 0.4% in the MDI group, resulting in a between-group treatment difference of 20.7% favoring the use of CSII. This significant improvement in glycemic control was not associated with severe hypoglycemia, ketoacidosis, or increased risk of cardiovascular events. In addition to this, the total daily insulin dose was 20.4% lower with pump therapy than MDI, without a significant difference for change in body weight between the two groups. HDL-cholesterol increased by 8% in the pump-therapy group and decreased by 7% in patients treated by MDI.
In our opinion, the grade A level of evidence associated with the results from OpT2mise study demonstrates that CSII may be an important valuable therapeutic option to the insulin treatment armamentarium for patients with type 2 diabetes failing to achieve treatment goals. This represents an additional therapeutic opportunity to address the unmet challenge of treating patients who are failing MDI and have a high-risk profile similar to participants in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial (3, 4) . The substantial decrease of HbA 1c in the CSII group was as safe as in control MDI arm. This magnitude of improvement in glycemic control has been consistently associated with a decrease in rates of microvascular complications (5) and to a lesser extent of macrovascular complications (6) and possibly with a slowing of cognitive decline (7 
